FDA inspection
Revance Therapeutics, Inc: FDA inspection ending Feb 27, 2025
FDA inspection 1262486 · Voluntary Action Indicated (VAI) · Newark, CA
Key facts
| Inspection ID | 1262486 |
|---|---|
| Firm | Revance Therapeutics, Inc |
| FEI number | 3007772056 |
| Address | 7555 Gateway Blvd |
| City | Newark |
| State | CA |
| ZIP | 94560 |
| Country | United States |
| Fiscal year | 2025 |
| Inspection end date | Feb 27, 2025 |
| Classification | Voluntary Action Indicated (VAI) |
| Project area | Drug Quality Assurance |
| Product type | Drugs |
At a glance
- 1–9 Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data